Intrathecal Drug Delivery Systems for Cancer Pain: A Health Technology Assessment.

CONCLUSIONS: Current evidence could not establish the benefit, harm, or cost-effectiveness of intrathecal drug delivery systems compared with current standards of care for managing refractory cancer pain in adults. Publicly funding intrathecal drug delivery systems for cancer pain would result in a budget impact of several hundred thousand dollars per year. PMID: 27026796 [PubMed - in process]
Source: Ontario Health Technology Assessment Series - Category: Journals (General) Tags: Ont Health Technol Assess Ser Source Type: research